semaglutide and klonopin vs. Tirzepatide: Which GLP-1 Wins? Semaglutide GLP-1 Receptor Agonist Research

Semaglutide has transformed weight loss treatment for millions, yet clinical data shows approximately 30% of patients experience inadequate response even at maximum doses

[1] [2] The Medicines and Healthcare products Regulatory Agency (MHRA) has approved this medication primarily for glycaemic control, while a higher dose formulation (Wegovy) is specifically licensed for weight management

Acknowledgments The authors extend their appreciation to the Deanship of Research and Graduate Studies at King Khalid University for funding this work through Large Research Project under grant number RGP2/112/46

Oral supplementation of turmeric attenuates proteinuria, transforming growth factor- and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: A randomized, double-blind and placebo-controlled study